Activity of menin inhibitor ziftomenib (KO-539) as monotherapy or in combinations against AML cells with MLL1 rearrangement or mutant NPM1

Warren Fiskus, Naval Daver, Steffen Boettcher, Christopher P. Mill, Koji Sasaki, Christine E. Birdwell, John A. Davis, Kaberi Das, Koichi Takahashi, Tapan M. Kadia, Courtney D. DiNardo, Francis Burrows, Sanam Loghavi, Joseph D. Khoury, Benjamin L. Ebert, Kapil N. Bhalla

Research output: Contribution to journalArticlepeer-review

3 Scopus citations
Original languageEnglish (US)
Pages (from-to)2729-2733
Number of pages5
Issue number11
StatePublished - Nov 2022

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this